Introduction – Continuous Intra-Peritoneal Insulin Infusion (CIPII) is an alternative treatment option for type 1 diabetes mellitus (T1DM) patients with frequent, unpredictable hypoglycaemia or progressive complications despite intensive subcutaneous therapy, with no published evidence thus far regarding its utilisation in Australia.

Objectives – Assess safety and efficacy of CIPII using the Diaport system at a Western Australian Tertiary Hospital.

Method – Observational analysis of 5 T1DM patients on the Diaport system. Patients interviewed and medical records including continuous blood glucose monitoring results reviewed to assess impact on hypoglycaemia, glycaemic control and quality of life (QOL) before and after CIPII. Complications with CIPII also assessed.

Results – 1 patient will only complete the minimum follow-up of 6 months by August 2015, and was excluded from the current analysis. All 4 patients that completed the minimum follow-up, demonstrated more predictable and less erratic blood glucose levels (BGLs) without major fluctuations and a significant reduction in hypoglycaemia. 3 demonstrated improvement in HbA1c (of up to 2.5%). The self-reported QOL and treatment satisfaction with CIPII was greater at 6 months. Catheter blockages, peri-portal cutaneous inflammation without peritonitis and catheter related pain were associated complications.

Conclusion – CIPII utilising the Diaport device is a potential alternative, to manage a subset of T1DM patients who demonstrate poor control despite intensive subcutaneous therapy, in Australia .